Premium
ANTITUMORAL ACTIVITY OF THE NOVEL BTK INHIBITOR TG‐1701 IS ASSOCIATED WITH DISRUPTION OF IKAROS SIGNALING AND IMPROVEMENT OF ANTI‐CD20 THERAPY IN B‐CELL NON‐HODGKIN LYMPHOMA
Author(s) -
Ribeiro M. L,
ReyesGarau D,
Vinyoles M,
ProfitosPeleja N,
Santos J. C,
Armengol M,
FernandezSerrano M,
BechSerra J. J,
Blecua P,
Musulen E,
De la Torre C,
Miskin H,
Esteller M,
Bosch F,
Menendez P,
Normant E,
Roue G
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.153_2880
Subject(s) - bruton's tyrosine kinase , cancer research , cd20 , antibody dependent cell mediated cytotoxicity , medicine , lymphoma , antibody , chemistry , biology , signal transduction , tyrosine kinase , immunology , monoclonal antibody , biochemistry